Bluejay Therapeutics has two product lines focused on the detection and care of hepatitis B. The funding from this round will go to support the clinical development of these drugs, according to the Aug. 16 Bluejay Therapeutics news release.
The series B funding round was led by Arkin Bio Ventures. Alon Lazarus, PhD, an investment manager at Arkin Bio Ventures, will join the Bluejay Therapeutics board of directors.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
